首页> 外文期刊>Modern Pathology >Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas
【24h】

Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas

机译:表皮生长因子受体介导的人肺癌下游分子激活的多样性

获取原文
       

摘要

The correlations among epidermal growth factor receptor (EGFR) gene amplification, gene mutation, overexpression/phosphorylation of EGFR protein and activation of its downstream molecules, signal transducers and activators of transcription 3 (Stat-3), Akt and extracellular signal-related protein kinase 1/2 (Erk1/2) were investigated in 28 cases of human lung carcinomas. In five cases of carcinomas with EGFR amplification, EGFR expression and phosphorylation levels were higher than other cases, and Stat-3 was activated in all five cases. Point mutations in the tyrosine kinase domain of EGFR were detected in five cases, one of which was also associated with gene amplification. In these five cases, both EGFR expression and phosphorylation were enhanced, and Akt was activated in four cases. In the remaining 19 cases, EGFR protein expression was upregulated in eight cases and phosphorylated in four cases, but neither EGFR nor phosphorylated-EGFR expression levels specifically correlated with activation of particular downstream molecules. In general, either Stat-3 or Akt, but not both, was activated reciprocally and complementarily to each other, as indicated by their phosphorylation. However, Erk1/2 was activated regardless of the status of Stat-3, Akt or EGFR proteins. The current data suggest that persistent Stat-3 activation may be a critical event downstream of EGFR that has been overexpressed by gene amplification. In contrast, tumor cells harboring the EGFR mutation may persistently activate a cascade via Akt. Finally, in the majority of cases that have no aberration of the EGFR, its downstream molecules function in reciprocal and/or complementary manner in the maintenance and/or progression of carcinomas. These overall results could provide novel insights into potential chemotherapeutic regimens for lung carcinomas, such as inhibitors of Stat-3, Akt and Erk1/2.
机译:表皮生长因子受体(EGFR)基因扩增,基因突变,EGFR蛋白的过表达/磷酸化及其下游分子,信号转导子和转录激活子3(Stat-3),Akt和细胞外信号相关蛋白激酶的激活之间的相关性在28例人类肺癌中调查了1/2(Erk1 / 2)。在五例EGFR扩增癌中,EGFR表达和磷酸化水平高于其他病例,并且Stat-5均在这五例中被激活。在五例中检测到EGFR酪氨酸激酶结构域中的点突变,其中之一也与基因扩增有关。在这五例中,EGFR的表达和磷酸化均得到增强,四例中Akt被激活。在其余的19例中,EGFR蛋白的表达在8例中被上调,在4例中被磷酸化,但EGFR和磷酸化EGFR的表达水平均与特定下游分子的激活无关。通常,Stat-3或Akt,但不是同时被彼此相互补充地激活,如它们的磷酸化所示。然而,无论Stat-3,Akt或EGFR蛋白的状态如何,Erk1 / 2均被激活。当前数据表明,持续的Stat-3激活可能是基因扩增过度表达的EGFR下游的关键事件。相反,具有EGFR突变的肿瘤细胞可能会通过Akt持续激活级联反应。最后,在大多数没有EGFR畸变的情况下,其下游分子在癌症的维持和/或进展中以相互和/或互补的方式起作用。这些总体结果可以为潜在的肺癌化疗方案提供新的见解,例如Stat-3,Akt和Erk1 / 2的抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号